BioCryst Pharmaceuticals, Inc.
BCRX
$7.97
$0.121.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.42% | 12.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.42% | 12.24% | |||
| Cost of Revenue | 1.31% | 10.39% | |||
| Gross Profit | -3.90% | 12.99% | |||
| SG&A Expenses | -5.00% | 5.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.82% | 7.45% | |||
| Operating Income | -0.65% | 40.32% | |||
| Income Before Tax | 87.02% | 755.67% | |||
| Income Tax Expenses | -154.89% | 92.98% | |||
| Earnings from Continuing Operations | 153.67% | 15,790.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 153.67% | 15,790.63% | |||
| EBIT | -0.65% | 40.32% | |||
| EBITDA | -0.63% | 39.69% | |||
| EPS Basic | 152.67% | 12,050.00% | |||
| Normalized Basic EPS | 38.99% | 1,282.61% | |||
| EPS Diluted | 200.00% | 19,900.00% | |||
| Normalized Diluted EPS | 39.60% | 1,277.27% | |||
| Average Basic Shares Outstanding | 0.31% | 0.30% | |||
| Average Diluted Shares Outstanding | 0.00% | 2.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||